keyword
highli
activ
antiretrovir
therapi
human
immunodefici
viru
tradit
chines
medicin
b
r
c
highli
activ
antiretrovir
therapi
haart
success
reduc
human
immunodefici
viru
hiv
morbid
mortal
sinc
introduct
howev
fail
erad
infect
high
cost
lifelong
highli
activ
antiretrovir
therapi
emerg
drug
resist
among
individu
brought
renew
pressur
discoveri
novel
antivir
altern
medicin
tradit
chines
medicin
tcm
complementari
altern
medicin
serv
rich
resourc
new
drug
develop
despit
almost
plantderiv
compound
clinic
trial
target
infect
studi
discov
sanguisorba
officinali
extract
soe
properti
use
cellbas
assay
singlecycl
luciferas
report
virus
pseudotyp
envelop
control
virus
found
soe
exhibit
signific
inhibitori
abil
tropic
ada
respect
ic
valu
ae
mgml
ae
mgml
soe
also
inhibit
simian
immunodefici
viru
infect
fail
block
vesicular
stomat
viru
sever
acut
respiratori
syndrom
coronaviru
influenza
pseudovirus
furthermor
show
soe
effect
postentri
event
replic
soe
pretreat
viru
cell
line
express
viral
receptor
show
maxim
inhibitori
activ
state
soe
probabl
block
entri
act
viral
envelop
directli
addit
soe
abl
inhibit
revers
transcriptas
inhibitor
resist
virus
proteas
inhibitor
resist
strain
find
demonstr
soe
novel
specif
entri
inhibitor
shed
light
discoveri
drug
tradit
herbal
medicin
extract
medicin
herb
sanguisorba
officinali
inhibit
entri
human
immunodefici
tradit
chines
medicin
tcm
includ
variou
form
herbal
medicin
acupunctur
moxibust
massag
qi
exercis
medit
dietari
therapi
tcm
develop
china
person
medic
practic
base
tradit
year
result
thousand
plant
use
herbal
medicin
treat
differ
type
diseas
exampl
one
famou
drug
artemisinin
origin
extract
plant
artemisia
annua
standard
treatment
worldwid
plasmodium
falciparum
malaria
past
decad
use
tcm
increas
global
one
mainstream
complementari
altern
medicin
also
serv
rich
resourc
new
drug
develop
prior
avail
highli
activ
antiretrovir
therapi
haart
peopl
human
immunodefici
viru
hiv
aid
often
sought
herbal
therapi
china
situat
continu
today
haart
still
readili
access
afford
especi
rural
area
major
patient
resid
even
era
haart
hivinfect
peopl
use
herbal
therapi
high
rate
sought
frequent
visit
tcm
provid
report
help
improv
treatment
case
howev
remain
unknown
whether
herb
use
antihiv
activ
therefor
unknown
regard
enhanc
patient
immun
function
treatment
hivrel
symptom
manag
haartrel
side
effect
recent
year
studi
demonstr
evidencebas
research
compound
extract
herbal
plant
elucid
biochem
activ
reveal
antitumor
activ
case
antihiv
activ
other
studi
herbal
compound
move
forward
clinic
trial
prior
studi
howev
unclear
sanguisorba
officinali
antihiv
activ
sanguisorba
officinali
also
call
great
burnet
plant
famili
rosacea
subfamili
rosoidea
easili
found
northern
region
china
use
tcm
thousand
year
treat
hemostasi
inflamm
function
discov
recent
year
includ
antioxid
antitumor
properti
best
knowledg
first
group
studi
activ
extract
officinali
soe
find
implic
explor
tcm
new
antivir
discoveri
materi
method
stem
officinali
cut
small
piec
immers
distil
water
mixtur
treat
ultrasound
hour
follow
boil
twice
c
minut
filtrat
supernat
concentr
j
u
r
n
l
f
f
n
r
u
g
n
l
es
rotari
evapor
reduc
pressur
follow
lyophil
hour
obtain
aqueou
extract
powder
soe
yield
soe
highperform
liquid
chromatographi
analysi
soe
conduct
ultim
column
mm
mm
welch
shanghai
china
mobil
phase
consist
acetonitril
formic
acid
b
water
use
gradient
elut
minut
e
minut
minut
e
minut
minut
minut
solvent
veloc
flow
mlminut
column
room
temperatur
detect
wavelength
set
nm
content
compon
control
respect
extract
powder
dissolv
phosphat
buffer
salin
pass
mm
filter
steril
soe
dissolv
dimethyl
sulfoxid
concentr
mgml
follow
gentl
vortex
room
temperatur
supernat
care
collect
centrifug
minut
filter
mm
millipor
syring
filter
experi
cell
line
mdck
cultur
dulbecco
modifi
eagl
medium
inactiv
fetal
bovin
serum
invitrogen
unitsml
penicillin
mgml
streptomycin
sulfat
invitrogen
ghost
cell
obtain
us
nation
institut
health
nih
bethesda
usa
aid
research
refer
reagent
program
cultur
dulbecco
modifi
eagl
medium
fetal
bovin
serum
unitsml
penicillin
mgml
streptomycin
sulfat
mgml
hygromycin
b
mgml
mgml
puromycin
sigma
aldrich
singlecycl
luciferas
hiv
ada
hiv
simian
immunodefici
viru
siv
siv
vesicular
stomat
viru
vsv
anhui
sever
acut
respiratori
syndrom
coronaviru
sarscov
pseudovirus
construct
describ
previous
briefli
pseudovirus
gener
cotransfect
cell
use
polyethylenimin
polysci
inc
warrington
pa
usa
eev
envelop
protein
differ
strain
virus
nonnucleosid
reversetranscriptas
inhibitor
nnrti
mutant
construct
gener
base
molecular
clone
backbon
eev
previous
describ
proteaseinhibitor
resist
strain
obtain
nih
resist
multipl
antihiv
proteas
drug
carri
cellfre
supernat
collect
hour
posttransfect
frozen
c
tissu
cultur
infect
dose
calcul
describ
previous
ghost
cell
incub
presenc
absenc
serial
dilut
soe
c
co
hour
cell
viabil
measur
use
commerci
avail
kit
celltiterglo
luminesc
cell
viabil
assay
kit
promega
usa
inhibitori
activ
soe
virus
evalu
describ
previous
briefli
serial
dilut
drug
test
viru
infect
tissu
cultur
infect
dose
ghost
use
hiv
ada
hiv
siv
siv
wherea
mdck
use
sarscov
pseudoviru
infect
respect
viral
infect
determin
day
measur
report
luciferas
activ
target
cell
postinfect
use
commerci
avail
kit
antivir
data
report
quantiti
drug
requir
inhibit
viral
product
ec
differ
polar
solvent
use
obtain
subfract
soe
yield
petroleumeetherpartit
extract
pe
ethylacetatepartit
extract
etoac
nbutanolpartit
extract
buoh
water
residu
subfract
concentr
vacuum
dryer
later
test
determin
antivir
activ
soe
cell
infect
ada
respect
presenc
serial
dilut
soe
control
vsv
pseudoviru
includ
parallel
experi
shown
fig
b
soe
display
ae
mgml
ae
mgml
inhibit
replic
coreceptor
tropism
without
observ
cell
toxic
fig
contrast
soe
test
vsv
pseudoviru
infect
inhibit
observ
ada
vsv
pseudovirus
share
hiv
backbon
differ
glycoprotein
express
viral
surfac
result
suggest
soe
act
specif
inhibit
replic
earli
stage
viral
entri
confirm
soe
antagon
viral
entri
rather
postentri
event
test
panel
virus
modifi
experiment
schedul
target
cell
first
coincub
pseudoviru
hour
wash
treat
presenc
mgml
soe
mm
azt
potent
nnrti
hour
shown
fig
experiment
schedul
soe
strongli
inhibit
anymor
compar
azt
result
support
find
inhibit
soe
replic
due
blockad
postentri
step
eg
revers
transcript
rather
entri
step
determin
whether
soe
inhibit
viru
entri
directli
inactiv
bind
receptor
target
cell
j
u
r
n
l
f
f
n
r
u
g
n
l
es
soeviru
bind
soecel
bind
assay
perform
soeviru
bind
assay
pseudoviru
pretreat
mgml
soe
first
meantim
dilut
solut
dimethyl
sulfoxid
use
neg
control
entri
inhibitor
enfuvirtid
posit
control
virus
recov
ultracentrifug
use
infect
target
cell
found
soe
inhibit
ada
pseudoviru
infect
similar
degre
block
fusion
fig
subsequ
soecel
bind
assay
perform
pretreat
target
ghost
cell
soe
antagonist
maraviroc
mvc
antagonist
posit
control
hour
c
wash
phosphat
buffer
salin
cell
incub
ada
hour
wash
cultur
c
hour
found
pretreat
target
cell
soe
virtual
antivir
effect
wherea
mvc
show
strong
inhibit
respect
ada
pseudovirus
expect
fig
demonstr
soe
inhibit
infect
act
viral
envelop
glycoprotein
mediat
viral
entri
host
target
cell
confirm
soe
entri
inhibitor
test
two
siv
one
influenza
one
sarscov
pseudovir
strain
previou
studi
indic
residu
peptid
found
potent
inhibitor
viru
entri
siv
envelop
glycoprotein
interestingli
soe
inhibit
siv
strain
neither
influenza
sarscov
fig
result
suggest
soe
broad
specif
reactiv
divers
aid
virus
rapid
emerg
drugresist
strain
patient
one
major
obstacl
success
antiretrovir
treatment
therefor
experi
involv
antihiv
resist
virus
carri
four
drugresist
strain
test
includ
three
nnrti
resist
virus
one
proteas
inhibitor
resist
viru
expect
soe
inhibit
four
drugresist
strain
fig
demonstr
greater
breadth
inhibit
compar
nevirapin
unit
state
food
drug
administrationapprov
nnrti
consist
previou
find
nevirapin
inhibit
resist
strain
harbor
mutat
fig
viral
entri
preced
revers
transcript
result
provid
support
soe
entri
inhibitor
live
replic
strain
character
antihiv
activ
aqueou
soe
extract
subject
differ
polar
solvent
obtain
pe
etoac
buoh
water
residu
fraction
vacuum
dri
screen
activ
etoac
buuoh
subfract
strongli
diminish
infect
target
cell
line
similar
soe
fig
howev
pe
subfract
show
inhibit
result
indic
solubl
soe
depend
polar
solvent
provid
direct
futur
isol
small
molecul
entri
inhibitor
subfract
studi
demonstr
soe
block
entri
strain
blockad
specif
soe
exhibit
activ
virus
pseudotyp
envelop
vsv
sarscov
influenza
interestingli
soe
act
directli
instead
cellular
receptor
coreceptor
also
exhibit
potenc
replic
compet
strain
resist
specif
drug
target
proteas
revers
transcriptas
rt
activ
find
therefor
provid
scientif
evid
potenti
use
soe
prevent
treatment
infect
search
small
molecular
compound
specif
entri
inhibitor
stop
enter
target
cell
critic
strategi
prevent
treatment
two
drug
categori
approv
fda
clinic
use
market
mvc
mvc
bind
host
coreceptor
prevent
bind
wherea
interact
interrupt
membran
fusion
host
target
cell
plasma
membran
part
repertoir
antiretrovir
drug
use
combin
therapi
treat
infect
although
effect
administr
inject
wherea
mvc
requir
screen
patient
exclud
strain
therefor
use
identifi
new
type
entri
inhibitor
end
great
interest
discov
soe
capabl
inhibit
entri
ada
strain
well
siv
siv
bind
viral
envelop
glycoprotein
directli
previous
shown
despit
signific
level
sequenc
divers
siv
share
seri
event
viru
entri
includ
bind
chemokin
coreceptor
fusion
viral
cellular
membran
soe
probabl
act
upon
highli
conserv
element
siv
envelop
glycoprotein
issu
still
requir
futur
investig
enter
target
cell
way
soe
probabl
inhibit
viru
entri
mechan
rather
block
bind
site
directli
critic
proven
specif
togeth
lack
antivir
effect
vsv
sarscov
influenza
also
rule
possibl
soe
simpli
inactiv
viru
act
viral
lipid
like
disinfect
support
find
sever
small
molecul
isol
plant
report
moder
inhibitori
abil
entri
exampl
polyphenol
found
green
tea
probabl
interrupt
membran
fusion
host
cell
plasma
membran
investig
necessari
reveal
mode
soe
action
may
lead
identif
new
drug
target
envelop
enhanc
effort
treatment
prevent
also
issu
rapid
emerg
drugresist
strain
especi
develop
countri
although
sever
extract
herbal
medicin
investig
antihiv
activ
inhibit
antihiv
drugresist
strain
rare
studi
recent
report
plantderiv
calanolid
analogu
uniqu
advantag
overcom
exist
drug
resist
virus
use
method
studi
show
soe
inhibit
rt
inhibitor
resist
virus
also
proteas
inhibitor
resist
primari
strain
rt
proteas
act
hiv
entri
result
consist
soe
new
entri
inhibitor
explor
potenti
soe
treat
aid
patient
futur
welldesign
clinic
trial
conduct
vivo
efficaci
evalu
also
necessari
purifi
small
molecul
compound
soe
activ
conclus
studi
demonstr
soe
block
entri
strain
blockad
soe
exhibit
activ
virus
pseudotyp
envelop
vsv
sarscov
influenza
interestingli
soe
act
directli
instead
cellular
receptor
coreceptor
also
exhibit
potenc
replicationcompet
strain
resist
specif
drug
target
proteas
rt
activ
find
therefor
provid
evid
potenti
use
soe
prevent
treatment
infect
well
search
small
molecular
compound
specif
entri
inhibitor
